Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

120.15 -1.37 (-1.13%)
Official Closing Price Updated: 8:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Biotech And Healthcare Stocks Lagging ↗
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
News headline image
“The One That Got Away” Stock Market (And Sentiment Results) ↗
It was very lonely being a bull last fall when the S&P 500 was in the 3600s to 3700s. The good news is there’s plenty of runway ahead. The bad news is, it’s going to be a bit more tricky. 
Via Talk Markets
News headline image
Market Mixes It Up With A Broad Rally ↗
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
News headline image
“Skip Or Flip” Stock Market (And Sentiment Results) ↗
We are at the cusp of a sea change, and the knock-on effects will be material. We expect to see two meaningful changes in the coming months as a result of the Fed being done. 
Via Talk Markets
News headline image
A Good Week For The Market But A Pause In The Biotech Rally ↗
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
News headline image
The Dierks Bentley “Feels Like Gold” Stock Market (And Sentiment Results) ↗
Markets top when everyone is overweight stocks on margin. We are nowhere close to that point 
Via Talk Markets
News headline image
Why These 3 Nasdaq Stocks Buckled Today ↗
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
News headline image
Time To Play Small Cap Life Science Stocks ↗
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
News headline image
Biotech ETFs Pop On M&A Resurgence ↗
The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A). 
Via Talk Markets
News headline image
Something Happened In Biotech Last Week ↗
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
News headline image
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector ↗
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
News headline image
Second Quarter Outlook For Biotech Stocks ↗
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
News headline image
“Knockin’ On Heaven’s Door” Stock Market (And Sentiment Results) ↗
We’ve come through the “point of control” on the S&P 500. This simply means there is less “overhead supply” to come on the market as we press higher. 
Via Talk Markets
News headline image
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
News headline image
Thermo Fisher, Principal Financial Group, And Two Promising ETFs Steal The Show On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named SPDR S&P Biotech ETF (NYSE: XBI), which is trading in a tight range < 
Via Benzinga
News headline image
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
News headline image
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
News headline image
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
News headline image
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
News headline image
Time to Spring-Clean...Your Stock Portfolio ↗
Plus, Howard Marks, co-founder of Oaktree Capital Management, joins the podcast to discuss topics including China's effect on inflation in the U.S. 
Via The Motley Fool
News headline image
April Is Busting Out For Healthcare And Biotech ↗
Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend. 
Via Talk Markets
News headline image
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗
 
Via Benzinga
News headline image
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags ↗
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
News headline image
The Stock Market Rally May Fizzle The Week Of April 3 ↗
I think what we’ve seen over the last week or two has been driven by systematic trading and rebalancing of portfolios, as investors have sold financials and moved into mega-cap technology names. But... 
Via Talk Markets
News headline image
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
News headline image
“Don’t Stop Believin'” Stock Market (And Sentiment Results) ↗
In this week’s AAII Sentiment Survey result, bullish percent ticked up to 22.5% from 20.9% the previous week. 
Via Talk Markets
News headline image
This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips ↗
T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment. 
Via The Motley Fool
News headline image
The 3 Best Growth Stocks to Buy in the Biotech Sector ↗
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
News headline image
Can Healthcare Stocks Survive Macro Headwinds? ↗
Healthcare stocks are supposed to be defensive plays in a choppy market. However, over the past 18 months, the XLV is flat and down 6% over one year. 
Via Talk Markets
News headline image
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
Via MarketBeat
Topics ETFs Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.